Compounded drugs go through a very different pathway at the FDA. Another misconception is that because a product lists the same active ingredients, it is equivalent to the name brand, she said
Current Pharmaceutical Design
In any case, it will take more studies to assess the effects in these populations.69,70 Current perspective and recommendations for improvement The 2025 American Diabetes Association (ADA) guidelines advise, with a level of recommendation A, the use of finerenone in patients with T2DM, CKD (eGFR 25 ml/min/1.73 m2) and albuminuria to reduce cardiovascular events and progression of CKD,11 whereas the 2024 Spanish Society of Nephrology consensus for the management of diabetic nephropathy suggests the use of finerenone in patients with T2DM, an eGFR 25 ml/min/1,73 m2, normal serum potassium concentration (5.1 mmol/l) and albuminuria (uACR 30 mg/g), despite the maximum tolerated doses of a RAASi, with a level of recommendation 1A.12 In short, the treatment of patients with CKD and T2DM should follow a comprehensive strategy, which requires a global approach that includes both the control of the different cardiovascular risk factors and the use of those drugs that have demonstrated a benefit at the renal and cardiovascular level, mainly ACEI or ARBs, SGLT2 inhibitors, finerenone and GLP-1 receptor agonists
The amount of weight you can expect to lose with Ozempic ( semaglutide ) as a GLP-1 medication varies from person to person, depending on factors like diet, exercise, and individual health conditions
The contradicting results from various studies suggest that thiopurine resistance may be a multifactorial phenomenon, in which the exact role of TPMT is clouded by the influences of multiple and possibly obscure pathways
Patients ask about it for chronic strain patterns, post-surgical healing, and sports recovery
